Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan

Motasem Al-Latayfeh,1,2 Mohammad Abdel Rahman,2 Raed Shatnawi1,2 1Department of General and Special Surgery, School of Medicine, The Hashemite University, Zarqa, Jordan; 2Department of Ophthalmology, Prince Hamza Hospital, Amman, JordanCorrespondence: Motasem Al-LatayfehThe Hashemite University, P.O...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Al-Latayfeh M, Abdel Rahman M, Shatnawi R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	diabetic macular edema dexamethasone anti-vegf ozurdex jordan Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d080acd68ae4425fb2f88e5984303b83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d080acd68ae4425fb2f88e5984303b83
record_format	dspace
spelling	oai:doaj.org-article:d080acd68ae4425fb2f88e5984303b832021-12-02T14:02:58ZOutcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan1177-5483https://doaj.org/article/d080acd68ae4425fb2f88e5984303b832021-03-01T00:00:00Zhttps://www.dovepress.com/outcome-of-single-dexamethasone-implant-injection-in-the-treatment-of--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Motasem Al-Latayfeh,1,2 Mohammad Abdel Rahman,2 Raed Shatnawi1,2 1Department of General and Special Surgery, School of Medicine, The Hashemite University, Zarqa, Jordan; 2Department of Ophthalmology, Prince Hamza Hospital, Amman, JordanCorrespondence: Motasem Al-LatayfehThe Hashemite University, P.O. Box 150495, Zarqa, 13115, JordanTel +962797397711Email motasem974@gmail.comPurpose: To analyze the real-life clinical outcome of a single dexamethasone implant (DEX) injection in the treatment of persistent diabetic macular edema (DME) after anti-vascular endothelial growth factor (anti-VEGF) agents in a sample of the Jordanian population.Methods: An observational case study design that involved a retrospective chart review analysis in a tertiary hospital in Amman, Jordan. Patients who showed persistent DME after receiving at least six doses of anti-VEGF agents for DME treatment were included.Results: The study population consisted of 72 participants (29 females, 43 males) having an average age of 66 years. All patients had best-corrected visual acuity (BCVA) less than 0.7 (6/9) and SD-OCT documented center-involved DME. The study results showed that the average baseline BCVA improved from 0.205± 0.1 before DEX injection to 0.358± 0.1 at 3 months post-injection (p< 0.0001). The central mean thickness (CMT) showed significant improvement also (539.347± 132.402 to 379.041± 99.430, p< 0.0001). There was a mean of 3 mmHg increase in intraocular pressure at 3 months post-injection (p< 0.0001), however, only 4% of patients required medical treatment. Other inflammatory biomarkers in OCT, such as intraretinal hyper-reflective dots (HRD), showed significant improvement also (23.67± 16 to 14.83± 13, p< 0.0001). No other significant safety concerns were noticed.Conclusion: A single DEX injection showed significant clinical and anatomical improvement in DME cases that are persistent after anti-VEGF treatment in our sample, with an excellent safety profile. In case of supply shortage of intravitreal injections, which occurs frequently at our center, a single DEX injection may be utilized as an effective DME therapy. Further research is mandated to identify clinical response in a larger sample and more frequent injections.Keywords: diabetic macular edema, dexamethasone, anti-VEGF, Ozurdex, JordanAl-Latayfeh MAbdel Rahman MShatnawi RDove Medical Pressarticlediabetic macular edemadexamethasoneanti-vegfozurdexjordanOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1285-1291 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic macular edema dexamethasone anti-vegf ozurdex jordan Ophthalmology RE1-994
spellingShingle	diabetic macular edema dexamethasone anti-vegf ozurdex jordan Ophthalmology RE1-994 Al-Latayfeh M Abdel Rahman M Shatnawi R Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
description	Motasem Al-Latayfeh,1,2 Mohammad Abdel Rahman,2 Raed Shatnawi1,2 1Department of General and Special Surgery, School of Medicine, The Hashemite University, Zarqa, Jordan; 2Department of Ophthalmology, Prince Hamza Hospital, Amman, JordanCorrespondence: Motasem Al-LatayfehThe Hashemite University, P.O. Box 150495, Zarqa, 13115, JordanTel +962797397711Email motasem974@gmail.comPurpose: To analyze the real-life clinical outcome of a single dexamethasone implant (DEX) injection in the treatment of persistent diabetic macular edema (DME) after anti-vascular endothelial growth factor (anti-VEGF) agents in a sample of the Jordanian population.Methods: An observational case study design that involved a retrospective chart review analysis in a tertiary hospital in Amman, Jordan. Patients who showed persistent DME after receiving at least six doses of anti-VEGF agents for DME treatment were included.Results: The study population consisted of 72 participants (29 females, 43 males) having an average age of 66 years. All patients had best-corrected visual acuity (BCVA) less than 0.7 (6/9) and SD-OCT documented center-involved DME. The study results showed that the average baseline BCVA improved from 0.205± 0.1 before DEX injection to 0.358± 0.1 at 3 months post-injection (p< 0.0001). The central mean thickness (CMT) showed significant improvement also (539.347± 132.402 to 379.041± 99.430, p< 0.0001). There was a mean of 3 mmHg increase in intraocular pressure at 3 months post-injection (p< 0.0001), however, only 4% of patients required medical treatment. Other inflammatory biomarkers in OCT, such as intraretinal hyper-reflective dots (HRD), showed significant improvement also (23.67± 16 to 14.83± 13, p< 0.0001). No other significant safety concerns were noticed.Conclusion: A single DEX injection showed significant clinical and anatomical improvement in DME cases that are persistent after anti-VEGF treatment in our sample, with an excellent safety profile. In case of supply shortage of intravitreal injections, which occurs frequently at our center, a single DEX injection may be utilized as an effective DME therapy. Further research is mandated to identify clinical response in a larger sample and more frequent injections.Keywords: diabetic macular edema, dexamethasone, anti-VEGF, Ozurdex, Jordan
format	article
author	Al-Latayfeh M Abdel Rahman M Shatnawi R
author_facet	Al-Latayfeh M Abdel Rahman M Shatnawi R
author_sort	Al-Latayfeh M
title	Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
title_short	Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
title_full	Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
title_fullStr	Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
title_full_unstemmed	Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan
title_sort	outcome of single dexamethasone implant injection in the treatment of persistent diabetic macular edema after anti-vegf treatment: real-life data from a tertiary hospital in jordan
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/d080acd68ae4425fb2f88e5984303b83
work_keys_str_mv	AT allatayfehm outcomeofsingledexamethasoneimplantinjectioninthetreatmentofpersistentdiabeticmacularedemaafterantivegftreatmentreallifedatafromatertiaryhospitalinjordan AT abdelrahmanm outcomeofsingledexamethasoneimplantinjectioninthetreatmentofpersistentdiabeticmacularedemaafterantivegftreatmentreallifedatafromatertiaryhospitalinjordan AT shatnawir outcomeofsingledexamethasoneimplantinjectioninthetreatmentofpersistentdiabeticmacularedemaafterantivegftreatmentreallifedatafromatertiaryhospitalinjordan
_version_	1718392110153990144

Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan

Ejemplares similares